GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303414 | Cervix | HSIL_HPV | regulation of response to wounding | 17/737 | 167/18723 | 3.26e-04 | 5.23e-03 | 17 |
GO:009875414 | Cervix | HSIL_HPV | detoxification | 16/737 | 152/18723 | 3.32e-04 | 5.31e-03 | 16 |
GO:190589715 | Cervix | HSIL_HPV | regulation of response to endoplasmic reticulum stress | 11/737 | 82/18723 | 3.58e-04 | 5.62e-03 | 11 |
GO:009723714 | Cervix | HSIL_HPV | cellular response to toxic substance | 14/737 | 124/18723 | 3.76e-04 | 5.89e-03 | 14 |
GO:00702061 | Cervix | HSIL_HPV | protein trimerization | 5/737 | 17/18723 | 3.89e-04 | 6.04e-03 | 5 |
GO:004576511 | Cervix | HSIL_HPV | regulation of angiogenesis | 27/737 | 342/18723 | 5.00e-04 | 7.22e-03 | 27 |
GO:0019372 | Cervix | HSIL_HPV | lipoxygenase pathway | 4/737 | 11/18723 | 6.30e-04 | 8.64e-03 | 4 |
GO:199074814 | Cervix | HSIL_HPV | cellular detoxification | 13/737 | 116/18723 | 6.46e-04 | 8.85e-03 | 13 |
GO:006104113 | Cervix | HSIL_HPV | regulation of wound healing | 14/737 | 134/18723 | 8.24e-04 | 1.07e-02 | 14 |
GO:190340911 | Cervix | HSIL_HPV | reactive oxygen species biosynthetic process | 9/737 | 64/18723 | 8.56e-04 | 1.10e-02 | 9 |
GO:200037714 | Cervix | HSIL_HPV | regulation of reactive oxygen species metabolic process | 15/737 | 157/18723 | 1.37e-03 | 1.56e-02 | 15 |
GO:00025264 | Cervix | HSIL_HPV | acute inflammatory response | 12/737 | 112/18723 | 1.53e-03 | 1.68e-02 | 12 |
GO:00712489 | Cervix | HSIL_HPV | cellular response to metal ion | 17/737 | 197/18723 | 2.07e-03 | 2.15e-02 | 17 |
GO:005159214 | Cervix | HSIL_HPV | response to calcium ion | 14/737 | 149/18723 | 2.29e-03 | 2.28e-02 | 14 |
GO:003210211 | Cervix | HSIL_HPV | negative regulation of response to external stimulus | 29/737 | 420/18723 | 2.53e-03 | 2.48e-02 | 29 |
GO:003497615 | Cervix | HSIL_HPV | response to endoplasmic reticulum stress | 20/737 | 256/18723 | 2.88e-03 | 2.70e-02 | 20 |
GO:007259314 | Cervix | HSIL_HPV | reactive oxygen species metabolic process | 19/737 | 239/18723 | 2.99e-03 | 2.76e-02 | 19 |
GO:00066907 | Cervix | HSIL_HPV | icosanoid metabolic process | 12/737 | 123/18723 | 3.36e-03 | 3.04e-02 | 12 |
GO:19034263 | Cervix | HSIL_HPV | regulation of reactive oxygen species biosynthetic process | 7/737 | 52/18723 | 4.07e-03 | 3.49e-02 | 7 |
GO:004544413 | Cervix | HSIL_HPV | fat cell differentiation | 18/737 | 229/18723 | 4.27e-03 | 3.64e-02 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALOX5 | SNV | Missense_Mutation | | c.1112N>A | p.Arg371Gln | p.R371Q | P09917 | protein_coding | tolerated(0.21) | benign(0.03) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
ALOX5 | insertion | In_Frame_Ins | novel | c.230_231insAAACTG | p.Asn78_Asp79insTrpAsn | p.N78_D79insWN | P09917 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ALOX5 | insertion | Nonsense_Mutation | novel | c.211_212insCTTCAACTTCCCAACCTTGATGAAAAGAGTGTT | p.Glu71delinsAlaSerThrSerGlnProTerTerLysGluCysTer | p.E71delinsASTSQP**KEC* | P09917 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ALOX5 | insertion | Nonsense_Mutation | novel | c.323_324insGTGA | p.Glu109Ter | p.E109* | P09917 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ALOX5 | insertion | Frame_Shift_Ins | novel | c.324_325insAAATTCTTAACACCTCCAGAACAAAGGCTCAG | p.Glu109LysfsTer15 | p.E109Kfs*15 | P09917 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ALOX5 | SNV | Missense_Mutation | rs778612367 | c.431G>A | p.Arg144Gln | p.R144Q | P09917 | protein_coding | deleterious(0.03) | possibly_damaging(0.764) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALOX5 | SNV | Missense_Mutation | novel | c.106C>T | p.His36Tyr | p.H36Y | P09917 | protein_coding | tolerated(0.41) | possibly_damaging(0.792) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALOX5 | SNV | Missense_Mutation | | c.883N>A | p.Ala295Thr | p.A295T | P09917 | protein_coding | tolerated(0.42) | benign(0.187) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
ALOX5 | SNV | Missense_Mutation | | c.685N>A | p.Glu229Lys | p.E229K | P09917 | protein_coding | deleterious(0.01) | benign(0.044) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALOX5 | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P09917 | protein_coding | tolerated(0.17) | possibly_damaging(0.771) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |